TRIAB-GPM is an advanced anti-diabetic formulation combining Glimepiride 2 mg, Pioglitazone 15 mg, and Metformin 500 mg (Sustained Release) to provide comprehensive blood sugar management for individuals with Type 2 Diabetes Mellitus. Available in tablet form, TRIAB-GPM delivers a triple-action approach to diabetes care by improving insulin secretion, enhancing insulin sensitivity, and reducing insulin resistance.

Designed to support balanced glucose management, TRIAB-GPM helps control both fasting and postprandial (PP) blood sugar levels, contributing to improved glycemic stability and long-term diabetes care.